Recent reports revealed that high baseline ANG-2 levels are associated with poor response to lenvatinib in unresectable HCC [11] and shorter PFS in advanced medullary thyroid cancer [17]. Here, ANGPT2 is linked to medullary thyroid gland carcinoma.